Trials / Completed
CompletedNCT03184480
Arnuity® Ellipta® Drug Use Investigation
Arnuity Ellipta Drug Use Investigation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 336 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The aim of this post-marketing investigation is to collect and assess the information about safety and effectiveness of ARNUITY® ELLIPTA® (hereinafter referred to as "Arnuity") in daily clinical practice. The investigation will include subjects with a diagnosis of asthma bronchial who are naïve to ARNUITY. The investigator will monitor the information about safety and effectiveness of ARNUITY for one year from the start date of ARNUITY administration and Pneumonia will be considered as the priority investigation matter. 300 subjects, from approximately 150 medical institutions, will be included in this analysis. ARNUITY ELLIPTA is the registered trademark of GlaxoSmithKline (GSK) group of companies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arnuity Ellipta | The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis. |
Timeline
- Start date
- 2017-08-19
- Primary completion
- 2021-03-17
- Completion
- 2021-03-17
- First posted
- 2017-06-12
- Last updated
- 2021-04-26
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03184480. Inclusion in this directory is not an endorsement.